MindMed Inc., a clinical-stage biopharmaceutical company, has announced the completion of enrollment and dosing in its Phase 2b study, MMED008, which focuses on the treatment of Generalized Anxiety Disorder (GAD) with MM-120 (lysergide D-tartrate). The study enrolled 198 participants, reaching a significant milestone in the company’s efforts to transform GAD treatment.

MindMed’s MMED008 study is a multi-center, double-blind, placebo-controlled trial that aimed to evaluate the effectiveness of MM-120. Participants were randomized to receive various doses of MM-120, and the primary objective is to measure its efficacy using the Hamilton Anxiety Rating Scale (HAM-A) from baseline to the fourth week. The company plans to release topline results in the fourth quarter of this year.

“Completion of enrollment of this study is a significant milestone for MindMed and moves us one step closer to our goal of transforming the treatment of GAD for the millions suffering from the disorder,” stated Robert Barrow, Chief Executive Officer and Director of MindMed. Nearly 200 participants were enrolled in just over a year, thanks to strong enthusiasm among both investigators and patients.

Secondary objectives of MindMed’s MMED008 include assessments of anxiety symptoms, safety, and tolerability, as well as other measures of efficacy and quality of life, all measured up to 12 weeks after the single administration. The study promises to add valuable data to the current understanding of GAD treatment, leveraging the unique properties of MM-120 in a clinical setting.

  Generalized Anxiety Disorder, lysergide D-tartrate, MindMed, MM-120, Robert Barrow, USA